Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.
|Motif Bio secures up to US$20 million debt financing|
November 15, 2017
|Motif Bio Presents New Pre-Clinical Data for Iclaprim at IDWeek 2017™|
October 6, 2017
|Motif Bio Announces Positive Topline Results for iclaprim in the REVIVE-2 Phase 3 Study|
October 4, 2017